1545MO - Personalised cancer prevention programme (Interception): A cost analysis to inform public policy decision-making

Background

Personalised cancer prevention pathways dedicated to individuals at high risk are developing rapidly. A cornerstone of these pathways resides in One-stop shops able to deliver information, education, and allow shared decision-making. The Interception programme, launched at Gustave Roussy in 2021, aims to build and demonstrate the value of personalized cancer prevention pathways for: women at high-risk of developing breast cancer (BC) either with genetic susceptibility factors or not, heavy smokers (HS) and people with a history of paediatric cancer (PC). We aimed to assess the operating cost of the One-stop Interception days to inform public policy decision-making.

Methods

Each pathway includes an on-site "One-Stop Interception Day” comprising medical visits and procedures, awareness and education workshops. We assessed the total operating cost per One-stop day and the cost per patient (pt) from the hospital’s perspective. We applied a mixed methodology using micro and gross costing. We valued medical and biological procedures from the French National Health Insurance perspective in 2022. To account for the uncertainty surrounding unit costs data, we considered 2 scenarios (low-cost/high-cost) using different assumptions.

Results

In 2022, 68 patients were admitted for the “genetic high risk” BC pathway, 94 for the “other BC high-risk”, 150 for HS and 190 for the PC pathway. For the high-cost scenario, the operating cost of One-stop day varied between € 2,018 for HS (per pt cost: € 504) to € 3,683 for the PC pathway (per pt cost: € 614). In the low-cost scenario, the operating cost varied between € 1,514 for HS (per pt cost: € 379) to € 2,978 for the PC pathway (per pt cost: € 496). High-risk BC pathway per-patient costs varied from € 292 to € 459 depending on the scenario. The main cost driver was staff which accounted for 37% to 77% of the total operating cost.

Conclusions

Our study provides an assessment of the costs of prevention pathways for people at increased risk of cancers, an essential prerequisite for informing decision-making in public health policy decisions. These results need to be combined to efficacy and cost-effectiveness data to expand the programme at a national level.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

A. Bayle: Financial Interests, Personal, Advisory Board, ASCO 2022 & ESMO 2023: Sanofi; Financial Interests, Personal, Invited Speaker, Health Economics conference: Roche; Financial Interests, Personal, Other, Expert at the Commission for the Evaluation of Diagnostic, Prognostic and Predictive Health Technologies: HAS (French National Authority for Health); Other, Transportation and accommodation support for the ASCO 2023 Congress: Pfizer. O. Caron: Financial Interests, Institutional, Advisory Board: Syantra. S. Delaloge: Financial Interests, Institutional, Advisory Board: Novartis, Sanofi, Gilead; Financial Interests, Institutional, Invited Speaker: Pfizer; Financial Interests, Institutional, Advisory Board, ad board: Besins Healthcare; Financial Interests, Institutional, Invited Speaker, ESMO symposium: Gilead; Financial Interests, Institutional, Advisory Board, scientific board: Elsan; Financial Interests, Institutional, Steering Committee Member: Roche Genentech, BMS, Sanofi; Non-Financial Interests, Member of Board of Directors, Société Française de Sénologie et Pathologie Mammaire: SFSPM; Non-Financial Interests, Principal Investigator, H2020 funding: European Commission. All other authors have declared no conflicts of interest.